1. Uso precoz de la eritropoyetina en la prevención de la anemia del prematuro
- Author
-
Salvadó G, Antonio, Ramolfo B, Pamela, Escobar M, Marisol, Núñez C, Alejandra, Aguayo T, Inés, Standen H, Jane, Sánchez G, Lina, and Cabello M, Angela
- Subjects
hemic and lymphatic diseases ,Infant, low birth weight ,Anemia neonatal ,Erythropoietin - Abstract
Background: Anemia is common among very low birth weight newborns and requires frequent blood tranfusions. Erythropoietin was been reported to be useful in the prevention of this anemia. Aim: To asses the benefits of early (before the third week of life) Human recombinant Erythropoietin (r-EPO) administration to reduce the requirement of blood tranfusions in very low birth weight newborns. Patients and methods: sixty newborns under 1500g of birthweight were randomly assigned to recive r-EPO (n=29) or placebo (n=31) three times per week, during four weeks. Packed red cell volume and reticulocyte counts were measured weekly. Serum erythropoietin was measured prior to eigth dose. Transfusion requirements were recorded. Results: r-EPO reduced transfusions from 1.41 ± 1.1 to 0.69 ± 1 transfusions/newborns (p
- Published
- 2000